Abstract
Hepatic drug transporters are mainly distributed in parenchymal liver cells (hepatocytes), contributing to drug’s liver disposition and elimination. According to their functions, hepatic transporters can be roughly divided into influx and efflux transporters, translocating specific molecules from blood into hepatic cytosol and mediating the excretion of drugs and metabolites from hepatic cytosol to blood or bile, respectively. The function of hepatic transport systems can be affected by interspecies differences and inter-individual variability (polymorphism). In addition, some drugs and disease can redistribute transporters from the cell surface to the intracellular compartments, leading to the changes in the expression and function of transporters. Hepatic drug transporters have been associated with the hepatic toxicity of drugs. Gene polymorphism of transporters and altered transporter expressions and functions due to diseases are found to be susceptible factors for drug-induced liver injury (DILI). In this chapter, the localization of hepatic drug transporters, their regulatory factors, physiological roles, and their roles in drug’s liver disposition and DILI are reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA et al (2008) The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br J Clin Pharmacol 66:233–239
Akira T (2006) Impact of transporter-mediated drug absorption, distribution, elimination and drug interaction in antimicrobial chemotherapy. J Infect Chemother 12:10
Aleksunes LM, Scheffer GL, Jakowski AB, Pruimboom-Brees IM, Manautou JE (2006) Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury. Toxicol Sci 89:370–379
Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M et al (2012) miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med 4:882–895
Allikmets R, Schriml L, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:3
Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV (2006) Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. Jaids J Acquir Immune Defic Syndr 42:441
Arrese M, Karpen SJ (2002) HNF-1 alpha: have bile acid transport genes found their "master"? J Hepatol 36:142–145
Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122–129
Backstrom G, Taipalensuu J, Melhus H, Brandstrom H, Svensson AC, Artursson P et al (2003) Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 18:359–364
Baghdasaryan A, Chiba P, Trauner M (2014) Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med 37:57–76
Ballatori NCW, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N (2005) OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42:10
Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB et al (2007) Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab Dispos 35:1963–1969
Barrios JM, Lichtenberger LM (2000) Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats. Gastroenterology 118:1179–1186
Belinsky Mg CZ, Shchaveleva I, Zeng H, Kruh GD (2002) Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62:6
Benichou C, Danan G, Flahault A (1993) Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46:1331–1336
Bergen Aa PA, Hu X, De Jong P, Gorgels TG (2007) ABCC6 and pseudoxanthoma elasticum. Pflugers Arch 453:7
Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y et al (2015a) Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol 71:341–355
Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y et al (2015b) Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol 71:329
Bjarnason I, Hayllar J, Macpherson AJ, Russell AS (1993) Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104:1832–1847
Bjornsson E, Jacobsen EI, Kalaitzakis E (2012) Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 56:374–380
Bjornsson ES (2017) Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 37:173–178
Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF et al (2006) Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963–988
Bohme M, Buchler M, Muller M, Keppler D (1993) Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333:193–196
Bohme M, Muller M, Leier I, Jedlitschky G, Keppler D (1994) Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 107:255–265
Bonder MJ, Kasela S, Kals M, Tamm R, Lokk K, Barragan I et al (2014) Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics 15:860
Bonin S, Pascolo L, Croce LS, Stanta G, Tiribelli C (2002) Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol Med 8:318–325
Borst PDWC, Van De Wetering K (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453:13
Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JH, Beijnen JH et al (2005) Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 5:123–131
Boyer Jl TM, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N (2006) Upregulation of a basolateral FXRdependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. American Journal of Physiology Gastrointestinal and Liver Physiology 290:7
Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ (2002) The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123:1649–1658
Callaghan R, Luk F, Bebawy M (2014) Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 42:623–631
Campion SN, Johnson R, Aleksunes LM, Goedken MJ, Van Rooijen N, Scheffer GL et al (2008) Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am J Physiol Gastrointest Liver Physiol 295:G294–G304
Cao X, Yu LX, Barbaciru C, Landowski CP, Shin HC, Gibbs S et al (2005) Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm 2:329–340
Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–473
Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol:261–283
Chan GN, Hoque MT, Bendayan R (2013) Role of nuclear receptors in the regulation of drug transporters in the brain. Trends Pharmacol Sci 34:361–372
Chang JH, Ly J, Plise E, Zhang X, Messick K, Wright M et al (2014) Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice. Drug Metab Dispos 42:1067–1073
Chen C, Chin J, Ueda K, Clark D, Pastan I, Gottesman M (1986) Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrugresistant human cells. Cell 47:9
Chen CSA, Dieter MZ, Tanaka Y, Scheffer GL, Klaassen CD (2005) Up-regulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats. Biochem Pharmacol 70:9
Chen J, Zhao KN, Liu GB (2013) Estrogen-induced cholestasis: pathogenesis and therapeuticimplications. Hepatogastroenterology 60:1289–1296
Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T et al (1999) Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219–1228
Chen Zs LK, Walther S, Raftogianis RB, Kuwanom Z et al (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:7
Cheng Y, El-Kattan A, Zhang Y, Ray AS, Lai Y (2016a) Involvement of drug transporters in organ toxicity: The fundamental basis of drug discovery and development. Chem Res Toxicol 29:545–563
Cheng Y, Woolf TF, Gan J, He K (2016b) In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review. Chem Biol Interact 255:23–30
Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97–104
Childs S, Yeh R, Georges E (1995) Identification of a sister gene to P-glycoprotein. Cancer Res 55:6
Choi JH, Ahn BM, Yi J, Lee JH, Nam SW, Chon CY et al (2007) MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17:403–415
Chojkier M (2005) Troglitazone and liver injury: in search of answers. Hepatology 41:237–246
Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y (1997a) Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 281:304–314
Chu XY, Kato Y, Sugiyama Y (1997b) Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57:1934–1938
Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA et al (1998) Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res 58:5137–5143
Cropp C, Komori T, Shima J, Urban T, Yee S, More S et al (2008) Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol 73:8
Cropp Cd KT, Shima JE, Urban TJ, Yee SW, More SS, Giacomini KM (2008) Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol 73:8
Crouthamel MH, Wu D, Yang Z, Ho RJY (2006) A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 95:2767–2777
Cui Y, Ko Nig J, Leier I (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:30
Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:1323–1330
Darling RL, Romero JJ, Dial EJ, Akunda JK, Langenbach R, Lichtenberger LM (2004) The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 127:94–104
Dawson PA, Hubbert ML, Rao A (2010) Getting the mOST from OST: Role of organic solute transporter, OSTα-OSTβ, in bile acid and steroid metabolism. Biochim Biophys Acta 1801:994–1004
Dawson S, Stahl S, Paul N, Barber J, Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130–138
De Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A et al (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889–5894
Delzenne NM, Calderon PB, Taper HS, Roberfroid MB (1992) Comparative hepatotoxicity of cholic acid, deoxycholic acid and lithocholic acid in the rat: in vivo and in vitro studies. Toxicol Lett 61:291–304
Dh S (2005) Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204:18
Di Paolo A, Bocci G, Danesi R, Del Tacca M (2006) Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 1:311–323
Dietrich CG, Ottenhoff R, De Waart DR, Oude Elferink RP (2001) Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 167:73–81
Djahanguiri B, Abtahi FS, Hemmati M (1973) Prevention of aspirin-induced gastric ulceration by bile duct or pylorus ligation in the rat. Gastroenterology 65:630–633
Dobson Pd DBK (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7:16
Dombrowski F, Stieger B, Beuers U (2006) Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 86:166–174
Dong Z, Ekins S, Polli JE (2015) Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. Eur J Pharm Sci 66:1–9
Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF (2003) P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73:223–231
Drewes T, Senkel S, Holewa B, Ryffel GU (1996) Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol 16:925–931
Elferink RP, Tytgat GN, Groen AK (1997) Hepatic canalicular membrane 1: The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. Faseb j 11:19–28
Emami Riedmaier A, Burk O, Van Eijck BA, Schaeffeler E, Klein K, Fehr S et al (2016) Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors. Pharmacogenomics J 16:341–351
Engevik AC, Goldenring JR (2018) Trafficking ion transporters to the apical membrane of polarized intestinal enterocytes. Cold Spring Harb Perspect Biol:10
Enokizono J, Kusuhara H, Sugiyama Y (2007) Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 35:209–214
Enomoto ATM, Shimoda M et al (2002) Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 301:6
Evers R, Chu X (2008) Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in durg disposition and hepatotoxicity. MolPharmacol 74:3
Evers R, Haas M, Sparidans R (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83:9
Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B et al (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231
Fehrenbach T, Cui Y, Faulstich H, Keppler D (2003) Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368:415–420
Fiorucci S, Mencarelli A, Cipriani S, Renga B, Palladino G, Santucci L et al (2011) Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. Br J Pharmacol 164:1929–1938
Fork C, Bauer T, Golz S, Geerts A, Weiland J, Del Turco D et al (2011) OAT2 catalyses efflux of glutamate and uptake of orotic acid. Biochem J 436:8
Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R et al (2002) Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 37:184–191
Friesema EC, Docter R, Moerings EP, Stieger B, Hagenbuch B, Meier PJ et al (1999) Identification of thyroid hormone transporters. Biochem Biophys Res Commun 254:5
Furihata T, Morio H, Zhu M, Suzuki Y, Ide H, Tsubota A et al (2017) Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet 32:116–119
Gao B, Yang FM, Yu ZT, Li R, Xie F, Chen J et al (2015) Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors. Int J Clin Exp Pathol 8:6995–7001
Gatlik-Landwojtowicz E, AäNismaa P, Seelig A (2006) Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45:13
Geier A, Martin IV, Dietrich CG, Balasubramaniyan N, Strauch S, Suchy FJ et al (2008) Hepatocyte nuclear factor-4alpha is a central transactivator of the mouse Ntcp gene. Am J Physiol Gastrointest Liver Physiol 295:G226–G233
Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J et al (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046–10050
Geyer J, Gavrilova O, Petzinger E (2009) Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice. J Vet Pharmacol Ther 32:87–96
Giacomini K, Huang S, Tweedie D (2012) Membrane transporters in drug development. Nature 9:22
Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–1530
Gores GJ, Miyoshi H, Botla R, Aguilar HI, Bronk SF (1998) Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases. Biochim Biophys Acta 1366:167–175
Gottesman Mm LV (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580:12
Gottesman Mm PI (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:43
Graham DJ, Green L, Senior JR, Nourjah P (2003) Troglitazone-induced liver failure: a case study. Am J Med 114:299–306
Graham DY, Opekun AR, Willingham FF, Qureshi WA (2005) Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 3:55–59
Green JL, Heard KJ, Reynolds KM, Albert D (2013) Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and Meta-analysis. West J Emerg Med 14:218–226
Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A et al (2016) Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer 16:94
Gu X, Manautou JE (2010) Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metab Rev 42:482–538
Gulbis B, Adler M, Ooms HA, Desmet JM, Leclerc JL, Primo G (1988) Liver-function studies in heart-transplant recipients treated with cyclosporin A. Clin Chem 34:1772–1774
Guo Y, Kotova E, Chen Z, Lee K, Hopper-Borge E, Belinsky M (2003) MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl) adenine. J Biol Chem 278:6
Haenisch S, Werk AN, Cascorbi I (2014) MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol 77:587–596
Haenisch S, Zimmermann U, Dazert E, Wruck C, Dazert P, Siegmund W et al (2007) Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7:56–65
Hagenbuch BDP (2004) The Sodium bile salt cotransport family SLC10. Pflugers Arch 447:5
Hagenbuch B, Stieger B (2013) The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 34:17
Han D, Dara L, Win S, Than TA, Yuan L, Abbasi SQ et al (2013) Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci 34:243–253
Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE et al (2008) Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59:69–75
Han JY, Lim HS, Yong HP, Lee SY, Jin SL (2009) Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 63:115
Hannivoort RA, Dunning S, Borght SV, Schroyen B, Woudenberg J, Oakley F et al (2008) Multidrug resistance-associated proteins are crucial for the viability of activated rat hepatic stellate cells. Hepatology 48:624–634
Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D et al (2010) HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20:112–120
He L, Yang Y, Guo C, Yao D, Liu HH, Sheng JJ et al (2014) Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus. Eur J Pharmacol 724:185–192
He MZS, Albers M, Baumeister SE, Rimmbach C, Nauck M, Wallaschofski H et al (2015a) Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet Genomics 25:8
He Y, Chevillet JR, Liu G, Kim TK, Wang K (2015b) The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs. Br J Pharmacol 172:2733–2747
Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Richards D, Storey J et al (2016) BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMC Gastroenterol 16:71
Heise MLA, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D et al (2012) Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 12:1
Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:7
Hirota T, Ieiri I (2015) Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol 11:1435–1447
Hirota T, Tanaka T, Takesue H, Ieiri I (2017) Epigenetic regulation of drug transporter expression in human tissues. Expert Opin Drug Metab Toxicol 13:19–30
Ho R, Choi L, Lee W, Mayo G, Schwarz U, Tirona R et al (2007) Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 17:647
Hoffmeyer S, Burk O, Richter OV, Arnold HP, Brockmöller J, Johne A et al (2000) Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 97:3473
Hong C, Nam Y (2014) Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics 4:32
Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M et al (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 1:696–702
Horikawa M, Kato Y, Sugiyama Y (2002) Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 19:1345–1353
Hua WY, Ding L, Chen Y, Gong B, He JC, Xu GL (2007) Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 44:931–937
Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z et al (2014) Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 14:370–384
Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I et al (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15:277–285
Ieiri I (2012) Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 27:21
Ieiri I, Higuchi S, Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703–729
Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K et al (2002) Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 47:285–310
Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S et al (2002) Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62:179–187
Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T et al (2002) C421A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q141K Protein and Low-Level Drug Resistance. Mol Cancer Ther 1:611–616
Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V et al (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867–872
Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T et al (2003) Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered Irinotecan. Drug Metab Pharmacokinet 18:212
Jacobsson Ja HT, Lindblom J, Fredriksson R (2007) Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family. Genomics 90:15
Jia W, Du F, Liu X, Jiang R, Xu F, Yang J et al (2015) Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. Drug Metab Dispos 43:10
Johnson Dr GG, Klaassen CD (2002) Expression of rat multidrug resistance protein 2 (Mrp2) in male and female rats during normal and pregnenolone-16alpha-carbonitrile (PCN)-induced postnatal ontogeny. Toxicology 178:11
Just G, Upeslacis J (1989) Novel polysaccharides novel macromolecular conjugates of the polysaccharides. European Patent Office
Kadmon M, Klunemann C, Bohme M, Ishikawa T, Gorgas K, Otto G et al (1993) Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 104:1507–1514
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (2015) Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 17:675–681
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (2016) Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes Obes Metab 18:925–929
Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y (2007) Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 22:287–298
Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P (2012) In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res 29:411–426
Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM et al (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908–2915
Kaur S, Siddiqui H, Bhat MH (2015) Hepatic progenitor cells in action liver regeneration or fibrosis? Am J Pathol 185:2342–2350
Kenna JG (2014) Current concepts in drug-induced bile salt export pump (BSEP) interference. Curr Protoc Toxicol 61:23.27.21–23.27.15
Keppler D (2014) The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 42:561–565
Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197–203
Kipp H, Arias I (2000) Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin Liver Dis 20:13
Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA (2016) Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med 9:97–106
Klaassen C, Aleksunes L (2010a) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:96
Klaassen CD, Aleksunes LM (2010b) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1–96
Kmiec Z (2001) Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 161:III–XIII. 1–151
Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J et al (2005a) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94
Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H (1999) pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83:491–496
Kobayashi MNT, Nishi K, Higaki Y, Okudaira H, Ono M, Tsujiuchi T, Mizutani A, Nishii R, Tamai I et al (2014) Transport mechanisms of hepatic uptake and bile excretion in clinical hepatobiliary scintigraphy with 99mTc-N-pyridoxyl-5-methyltryptophan. Nucl Med Biol 41:5
Kobayashi YON, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T (2005b) Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 57:6
Kock K, Brouwer KLR (2012) A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther 92:599–612
Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34:413–435
Kong LL, Zhuang XM, Yang HY, Yuan M, Xu L, Li H (2015) Inhibition of P-glycoprotein gene expression and function enhances Triptolide-induced hepatotoxicity in mice. Sci Rep 5:11747
König J, Cui Y, Nies AT, Keppler D (2000) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161–23168
Kool M, De Haas M, Scheffer GL, Scheper RJ, Van Eijk MJ, Juijn JA et al (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–3547
Kool M, Van Der Linden M, De Haas M, Scheffer GL, De Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Schepter RJ et al (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6
Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Takamura M et al (2010) Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 23:965–972
Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E et al (2000) The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 28:1192–1197
Kostrubsky VE, Vore M, Kindt E, Burliegh J, Rogers K, Peter G et al (2001) The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab Dispos 29:1561–1566
Kovacsics D, Patik I, Ozvegy-Laczka C (2017) The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions. Expert Opin Drug Metab Toxicol 13:409–424
Krishnamurthy PS (2006) Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol 46:30
Kromer A, Moosmann B (2009) Statin-Induced Liver Injury Involves Cross-Talk between Cholesterol and Selenoprotein Biosynthetic Pathways. Mol Pharmacol 75:1421–1429
Kruh G, Guo Y, Hopper-Borge E, Belinsky M, Chen Z (2007) ABCC10, ABCC11, and ABCC12. Pflugers Arch. 453:10
Kullak-Ublick G, Ismair MG, Kubitz R, Schmitt M, Haussinger D, Stieger B et al (2000) Stable expression and functional characterization of a Na+−taurocholate cotransporting green fluorescent protein in human hepatoblastoma HepG2 cells. Cytotechnology 34:9
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F et al (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:9
Kullak-Ublick GA, Stieger B, Meier PJ (2004) Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126:322–342
Kunze A, Huwyler J, Camenisch G (2014) Prediction of organic aniontransporting polypeptide 1B1- and 1B3- mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos 42:8
Kuppens IE, Breedveld P, Beijnen JH, Schellens JH (2005) Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 23:443–464
Kurz A, Graf D, Schmitt M, Vom Dahl S, Häussinger D (2001) Tauroursodeoxycholate-induced choleresis involves p38 (MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 121:13
Kwo P, Patel T, Bronk SF, Gores GJ (1995) Nuclear serine protease activity contributes to bile acid-induced apoptosis in hepatocytes. Am J Physiol 268:G613–G621
Kwon M, Choi YA, Choi MK, Song IS (2015) Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. Arch Pharm Res 38:849–856
Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:9
Lai Y (2009) Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin Drug Metab Toxicol 5:13
Lapham K, Novak J, Marroquin LD, Swiss R, Qin S, Strock CJ et al (2016) Inhibition of hepatobiliary transport activity by the antibacterial agent Fusidic Acid: Insights into factors contributing to Conjugated Hyperbilirubinemia/Cholestasis. Chem Res Toxicol
Lau YY, Huang Y, Frassetto L, Benet LZ (2007) effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204
Le Thai B, Dumont M, Michel A, Erlinger S, Houssin D (1988) Cholestatic effect of cyclosporine in the rat. An inhibition of bile acid secretion. Transplantation 46:510–512
Le Vee M, Gripon P, Stieger B, Fardel O (2008) Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos 36:217–222
Le Vee M, Lecureur V, Stieger B, Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 37:685–693
Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ (1996) Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063–12067
Lee SS, Jeong HE, Yi JM, Jung HJ, Jang JE, Kim EY et al (2007) Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab Dispos 35:623
Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807–27810
Leslie EM, Deeley RG, SPC C (2005) Multidrug resistance proteins in toxicology: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology 204:22
Leslie EM, Watkins PB, Kim RB, Brouwer KL (2007) Differential inhibition of rat and human Na+−dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170–1178
Letschert K, Keppler D, König J (2004) Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14:441–452
Lewis JH (2015) The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol 13:2173–2189.e2178
Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE et al (2007) Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6:432–438
Li L, Tu M, Yang X, Sun S, Wu X, Zhou H et al (2014) The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity. Drug Metab Dispos 42:1227–1234
Li X, Zhong K, Guo Z, Zhong D, Chen X (2015) Fasiglifam (TAK-875) inhibits hepatobiliary transporters: A possible factor contributing to Fasiglifam-induced liver injury. Drug Metab Dispos 43:1751–1759
Ligumsky M, Golanska EM, Hansen DG, Kauffman GL Jr (1983) Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 84:756–761
Ligumsky M, Sestieri M, Karmeli F, Zimmerman J, Okon E, Rachmilewitz D (1990) Rectal administration of nonsteroidal antiinflammatory drugs. Effect on rat gastric ulcerogenicity and prostaglandin E2 synthesis. Gastroenterology 98:1245–1249
Liu Y, Zheng X, Yu Q, Wang H, Tan F, Zhu Q et al (2016) Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci Transl Med 8
Liu YT, Hao HP, Xie HG, Lai L, Wang QO, Liu CX et al (2010) Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 38:1779–1784
Liu YT, Hao HP, Xie HG, Lv H, Liu CX, Wang GJ (2009) Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of Berberine in rats. J Pharm Sci 98:4391–4401
Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pinan MA, Garcia-Miguel P, Navajas A et al (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:612–619
Lozano E, Herraez E, Briz O, Robledo VS, Hernandez-Iglesias J, Gonzalez-Hernandez A et al (2013) Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int 2013:692071
Lu H, Choudhuri S, Ogura K, Csanaky IL, Lei X, Cheng X et al (2008) Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol Sci 103:35–45
Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y et al (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575–581
Maeda T, Wakasawa T, Funabashi M, Fukushi A, Fujita M, Motojima K et al (2008) Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. Biol Pharm Bull 31:1230–1236
Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE et al (2008) Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106:319–328
Malik MY, Jaiswal S, Sharma A, Shukla M, Lal J (2016) Role of enterohepatic recirculation in drug disposition: cooperation and complications. Drug Metab Rev 48:281–327
Manautou JE, De Waart DR, Kunne C, Zelcer N, Goedken M, Borst P et al (2005) Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091–1098
Mano Y, Usui T, Kamimura H (2007) Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 28:13–18
Mao Q, Unadkat JD (2015) Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J 17:65–82
Mao Q (2015) Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update. AAPS J 17:18
Marada VV, Florl S, Kuhne A, Muller J, Burckhardt G, Hagos Y (2015) Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs. Pharmacol Res 91:78–87
Materna V, Liedert B, Thomale J, Lage H (2005) Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 115:393–402
Matsunaga N, Kaneko N, Staub AY, Nakanishi T, Nunoya K, Imawaka H et al (2016) Analysis of the metabolic pathway of bosentan and of the cytotoxicity of bosentan metabolites based on a quantitative modeling of metabolism and transport in sandwich-cultured human hepatocytes. Drug Metab Dispos 44:16–27
Mayo SA, Song YK, Cruz MR, Phan TM, Singh KV, Garsin DA et al (2016) Indomethacin injury to the rat small intestine is dependent upon biliary secretion and is associated with overgrowth of enterococci. Physiological Reports 4:e12725
Mei Q, Richards K, Strong-Basalyga K, Fauty SE, Taylor A, Yamazaki M et al (2004) Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome p450 3A1/2. J Pharm Sci 93:2488–2496
Meier-Abt F, Faulstich H, Hagenbuch B (2004) Identification of phalloidin uptake systems of rat and human liver. Biochim Biophys Acta 1664:64–69
Meier PJ (2002) Canalicular bile formation: beyond single transporter functions. J Hepatol 37:272–273
Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:11
Merino G, Jonker JW, Wagenaar E, Van Herwaarden AE, Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758–1764
Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G et al (2011) PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 21:679–686
Miriam Cantore RR, Sommerfeld A, Becker M, Häussinger D (2011) The Src family kinase Fyn mediates hyperosmolarity-induced Mrp2 and Bsep retrieval from canalicular membrane. J Biol Chem 286:16
Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Af H et al (2006) Inhibition of bile acid transport across Na+/taurocholate contransporting polypeptide (SLC10A1) and bile salt export pump (ABCB11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:7
Mizuarai S, Aozasa N, † HK (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238–246
Monks Nr LS, Xu Y, Yu H, Bendelow AS, Moscow JA (2007) Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol Cancer Ther 6:587
Morisaki K, Robey RW, Ozvegylaczka C, Honjo Y, Polgar O, Steadman K et al (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161–172
Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N et al (2002) Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25:1356–1359
Moriyama Y, Hiasa M, Matsumoto T, Omote H (2008) Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica 38:1107–1118
Moseley RH (1997) Sepsis-associated cholestasis. Gastroenterology 112:302–306
Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y (2006) Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074–1084
Nakabori T, Hikita H, Murai K, Nozaki Y, Kai Y, Makino Y et al (2016) Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver. Sci Rep:6
Nakajima M, Yokoi T (2011) MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther 131:330–337
Niemi M, Pasanen M, Neuvonen P (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:81
Nies AT, Keppler D (2007) The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453:643–659
Nies AT, Koepsell H, Damme K, Schwab M (2010) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201:63
Niesat KH, Winter S, Burk O, Klein K, Kerb R et al (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:14
Ning B, Su Z, Mei N, Hong H, Deng H, Shi L et al (2014) Toxicogenomics and cancer susceptibility: advances with next-generation sequencing. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 32:121–158
Nishimura M, Yamaguchi M, Yamauchi A, Ueda N, Naito S (2005) Role of soybean oil fat emulsion in the prevention of hepatic xenobiotic transporter mRNA up- and down-regulation induced by overdose of fat-free total parenteral nutrition in infant rats. Drug Metab Pharmacokinet 20:46–54
Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K et al (2014) Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 60:723–731
Noguchi KK, Sugimoto Y (2014) Human ABC transporter ABCG2/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers. Med 7:12
Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y et al (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804–813
Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F (2013) Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet 52:751–762
Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A et al (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:10
Oostendorp RL, Buckle T, Beijnen JH, Van Tellingen O, Schellens JH (2009) The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31–40
Otieno MA, Snoeys J, Lam W, Ghosh A, Player MR, Pocai A et al (2017a) Fasiglifam (TAK-875): Mechanistic investigation and retrospective identification of hazards for Drug Induced Liver Injury (DILI). Toxicol Sci
Otieno MA, Snoeys J, Lam W, Ghosh A, Player MR, Pocai A et al (2017b) Fasiglifam (TAK-875): Mechanistic investigation and retrospective identification of hazards for drug induced liver injury. Toxicol Sci
Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y (2005) A humantransporter protein that mediates the final excretion step for toxic organiccations. Proc Natl Acad Sci U S A 76:10
Oude Elferink RP, Beuers U (2011) Targeting the ABCB4 gene to control cholesterol homeostasis. Expert Opin Ther Targets 15:1173–1182
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of Atorvastatin and Rosuvastatin. Clin Pharmacol Ther 82:726–733
Patel M, Taskar KS, Zamek-Gliszczynski MJ (2016) Importance of hepatic transporters in clinical disposition of drugs and their metabolites. J Clin Pharmacol 56(Suppl 7):S23–S39
Patel T, Steer CJ, Gores GJ (1999) Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis. Hepatology 30:811–815
Paulusma CC, Kool M, Bosma PJ, Scheffer GL, Ter Borg F, Scheper RJ et al (1997) A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25:1539–1542
Polgar O, Robey RW, Bates SE (2008) ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4:1–15
Priyamvada C, Kim L (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21:17
Reid G, Wielinga P, Zelcer N, Haas MD, Deemter LV, Wijnholds J et al (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63:10
Reuter BK, Davies NM, Wallace JL (1997) Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112:109–117
Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259
Ringseis R, Posel S, Hirche F, Eder K (2007) Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate causes upregulation of organic cation transporter 2 in liver and small intestine of rats. Pharmacol Res 56:175–183
Ripperger A, Benndorf RA (2016) The C421A (Q141K) polymorphism enhances the 3′-untranslated region (3’-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2. Biochem Pharmacol 104:139–147
Rodrigues AD, Lai Y, Cvijic ME, Elkin LL, Zvyaga T, Soars MG (2014) Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump. Drug Metab Dispos 42:566–574
Roman ID, Coleman R (1994) Disruption of canalicular function in isolated rat hepatocyte couplets caused by cyclosporin A. Biochem Pharmacol 48:2181–2188
Roman ID, Fernandez-Moreno MD, Fueyo JA, Roma MG, Coleman R (2003) Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol Sci 71:276–281
Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A, Jimenez R (1990) Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology 12:83–91
Ros JE, Roskams TA, Geuken M, Havinga R, Splinter PL, Petersen BE et al (2003) ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut 52:1060–1067
Rukov JL, Vinther J, Shomron N (2011) Pharmacogenomics genes show varying perceptibility to microRNA regulation. Pharmacogenet Genomics 21:251–262
Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137–174
Russo MW, Scobey M, Bonkovsky HL (2009) Drug-induced liver injury associated with statins. Semin Liver Dis 29:412–422
Sadighara M, Amirsheardost Z, Minaiyan M, Hajhashemi V, Naserzadeh P, Salimi A et al (2017) Toxicity of atorvastatin on pancreas mitochondria: A justification for increased risk of diabetes mellitus. Basic Clin Pharmacol Toxicol 120:131–137
Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T et al (2010) Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66:95–105
Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:24
Schaeffeler EHC, Nies AT, Winter S, Kruck S, Hofmann U et al (2011) DNA methylation is associated with downregulation of the oranic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 3:1
Schoen RT, Vender RJ (1989) Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 86:449–458
Seferian A, Simonneau G (2013) Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev 22:217–226
Sheng J, Tian X, Xu G, Wu Z, Chen C, Wang L et al (2015) The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism. Drug Metab Dispos 43:63–72
Shin HJ, Anzai N, Enomoto A, He X, Kim DK, Endou H et al (2007) Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate. Hepatology 45:1046–1055
Shitara YHT, Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pham Sci 27:22
Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616
Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45–78
Simonneau G, Galie N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A et al (2014) Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 172:332–339
Singh S, Hynan LS, Lee WM (2013) Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 58:1397–1402
Slaviero KA, Clarke SJ, Rivory LP (2003) Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4:224–232
Slijepcevic D, Kaufman C, Wichers CG, Gilglioni EH, Lempp FA, Duijst S et al (2015) Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice. Hepatology 62:207–219
Slijepcevic D, Van De Graaf SF (2017) Bile acid uptake transporters as targets for therapy. Dig Dis 35:251–258
Small DM (2003) Role of ABC transporters in secretion of cholesterol from liver into bile. Proc Natl Acad Sci U S A 100:4–6
Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K et al (2007) Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81:76–82
Smitherman PK, Townsend AJ, Kute TE, Morrow CS (2004) Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1–1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 308:260–267
Snow KL, Moseley RH (2007) Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci 80:732–740
Soichiro Matsushima KM, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y (2008) Involvement of multiple efflux transporters in hepatic disposition of Fexofenadine. Mol Pharmacol 73:10
Soroka C, Lee J, Azzaroli F, Boyer J (2001a) Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33:9
Soroka C, Lee J, Azzaroli F, Boyer J (2001b) Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33:783–791
Soroka CJ, Ballatori N, Boyer JL (2010) Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. Semin Liver Dis 30:178–185
Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ et al (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54:1767–1776
Staud F, Cerveny L, Ahmadimoghaddam D, Ceckova M (2013) Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics. Int J Biochem Cell Biol 45:2007–2011
Stein U, Walther W, Wunderlich V (1994) Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 10:1541–1545
Stieger B (2010a) Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug metabolism Reviews 42:9
Stieger B (2010b) Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev 42:437–445
Stieger B, Beuers U (2011) The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. Curr Drug Targets 12:661–670
Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422–430
Stone B, Warty V, Dindzans V, Van Thiel D (1988) The mechanism of cyclosporine-induced cholestasis in the rat. Transplant Proc 20:841–844
Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L et al (2010) Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 9:597–614
Sun J, Zhang HY, Li LY, Yu LF, Fu LF (2017) MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. Oncology Reports 37:1698–1706
Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584–590
Tamai I (2013) Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos 34:29–44
Tamai I, Ohashi R, Nezu J, et al (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273:5
Tamai I, Yabuuchi H, Nezu J, et al (1997) Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419:5
Tamura A, Wakabayashi K, Onishi Y, Takeda M, Ikegami Y, Sawada S et al (2007) Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98:231–239
Tan DN, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M et al (2012) Functional characterization of ABCC2 promoter polymorphisms and allele specific expression. Pharmacogenomics J 13:396
Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:6
Taylor R (2004) Causation of type 2 diabetes – the Gordian knot unravels. N Engl J Med 350:639–641
Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant 2012:230386
Telbisz A, Homolya L (2016) Recent advances in the exploration of the bile salt export pump (BSEP/ABCB11) function. Expert Opin Ther Targets 20:501–514
Thakkar N, Lockhart AC, Lee W (2015) Role of Organic Anion-Transporting polypeptides (OATPs) in cancer therapy. AAPS J 17:535–545
Theis JGW (1998) Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporine. Int J Clin Pharmacol Ther 36:4
Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7:678–693
Tian Y, Bian Y, Jiang Y, Qian S, Yu A, Zeng S (2015) Interplay of Breast Cancer Resistance Protein (BCRP) and metabolizing enzymes. Curr Drug Metab 16:17
Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675
TranV Gorboulev, Ulzheimer JC, Akhoundova A (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:11
Trauner M, Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633–671
Trauner M, Fickert P, Wagner M (2007) MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 27:77–98
Trauner M, Fuchs CD, Halilbasic E, Paumgartner G (2017) New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology 65:1393–1404
Treiber A, Schneiter R, Hausler S, Stieger B (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400–1407
Tu M, Sun S, Wang K, Peng X, Wang R, Li L et al (2013) Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. Toxicology 311:225–230
Verrier Er CC et al (2016) Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytes. Cell Report 17:12
Vildhede AWSJ, Norén A, Karlgren M, Artursson P (2015) Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure. J Proteome Res 14:10
Vlaming ML, Pala Z, Van Esch A, Wagenaar E, De Waart DR, Van De Wetering K et al (2009a) Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 15:3084–3093
Vlaming ML, Van EA, Pala Z, Wagenaar E, Van DWK, Van TO et al (2009b) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8:3350–3359
Vlaming ML, Van Esch A, Pala Z, Wagenaar E, Van De Wetering K, Van Tellingen O et al (2009c) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8:3350–3359
Vos T, Hooiveld GJE, Konong H, Childs S, Meijer DKF, Moshage H et al (2006) Up-regulation of the multidrug resistance genes, mrp1 and mdr1b, and down regulation of the organic anion transporter, mrp2, and the bile salt transporter, spgp, in endotoxemic rat liver. Hepatology 43:S9–S11
Vos TA, Ros JE, Havinga R, Moshage H, Kuipers F, Jansen PLM et al (1999) Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology 29:1833–1839
Sun W, Wu RR, van Poelje PD, Erion MD (2001) Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun 283:417–422
Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129
Wagner M, Zollner G, Trauner M (2009) New molecular insights into the mechanisms of cholestasis. J Hepatol 51:565–580
Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704
Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z et al (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106:4402–4407
Wang L, Ma L, Lin Y, Liu X, Xiao L, Zhang Y et al (2018) Leflunomide increases hepatic exposure to methotrexate and its metabolite by differentially regulating multidrug resistance-associated protein Mrp2/3/4 transporters via peroxisome proliferator-activated receptor alpha activation. Mol Pharmacol 93:563–574
Wang L, Prasad B, Salphati L, Chu X, Gupta A, Hop CE et al (2015) Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics. Drug Metab Dispos 43:367–374
Watanabe S, Yokoyama Y, Oda K, Kokuryo T, Shoda J, Okada K (2009a) Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. Hepatol Res 39:9
Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y (2009b) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–662
Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL (2009) Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. Hepatology 50:1588–1596
Weinman SA (1997) Electrogenicity of Na(+)-coupled bile acid transporters. Yale J Biol Med 70:331–340
Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D (2011) Effect of Gemfibrozil and Fenofibrate on the pharmacokinetics of Atorvastatin. J Clin Pharmacol 51:378–388
Wieland T (1983) The toxic peptides from Amanita mushrooms. Int J Pept Protein Res 22:257–276
Wolenski FS, Zhu AZ, Johnson M, Yu S, Moriya Y, Ebihara T et al (2017) Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury. Toxicol Sci
Wolf KK, Vora S, Webster LO, Generaux GT, Polli JW, Brouwer KL (2010) Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. Toxicol In Vitro 24:297–309
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (2015) Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: Update of the literature. Clin Pharmacokinet 54:709–735
Wu TY, Khor TO, Lee JH, Cheung KL, Shu L, Chen C et al (2013) Pharmacogenetics, pharmacogenomics and epigenetics of Nrf2-regulated xenobiotic-metabolizing enzymes and transporters by dietary phytochemical and cancer chemoprevention. Curr Drug Metab 14:688–694
Wu X, Prasad PD, Leibach FH, Ganapathy V (1998) cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 246:7
Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES et al (2001) An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 98:3375–3380
Xu FQ, Xu FC, Hou B, Fan WW, Zi CT, Li Y et al (2014) Cytotoxic bibenzyl dimers from the stems of Dendrobium fimbriatum Hook. Bioorg Med Chem Lett 24:5268–5273
Yabuuchi H, Tanaka K, Maeda M, Takemura M, Oka M, Ohashi R et al (2008) Cloning of the dog bile salt export pump (BSEP; ABCB11) and functional comparison with the human and rat proteins. Biopharm Drug Dispos 29:441–448
Yamazaki M, Suzuki H, Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497–513
Yan H, Zhong GC, Xu GW, He WH, Jing ZY, Gao ZC et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1
Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N et al (2014) Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology 86:53–62
Yasumiba S, Tazuma S, Ochi H, Chayama K, Kajiyama G (2001) Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats. Biochem J 354:591–596
Yokoi T, Nakajima M (2013) microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53:377–400
Yonezawa A, Ken-Ichi I (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol 164:9
Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD et al (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19–28
Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM (2012) Highlights from the international transporter consortium second workshop. Clin Pharmacol Ther 92:553–556
Zelcer NST, Reid G et al (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:8
Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A et al (2006a) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847–8857
Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ et al (2006b) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99–103
Zhang XY, Yang J, Yin XF, Liu XD, Wang GJ (2009) Hepatobiliary transport of glutathione and its role in cholestasis. Yao Xue Xue Bao 44:327–332
Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159
Zhang YK, Wang YJ, Gupta P, Chen ZS (2015) Multidrug Resistance Proteins (MRPs) and cancer therapy. AAPS J 17:802–812
Zhou L, Song Y, Zhao J, Qin H, Zhang G, Zhou Y et al (2016) Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver. Pharm Biol 54:931–937
Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K et al (2005) Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25:367–379
Acknowledgments
This chapter was completed with the help of Yaru Xue, Li Han, Ying Wang, Le Wang, and other students of Dr. Guoyu Pan.
Funding
TBD
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pan, G. (2019). Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity. In: Liu, X., Pan, G. (eds) Drug Transporters in Drug Disposition, Effects and Toxicity. Advances in Experimental Medicine and Biology, vol 1141. Springer, Singapore. https://doi.org/10.1007/978-981-13-7647-4_6
Download citation
DOI: https://doi.org/10.1007/978-981-13-7647-4_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7646-7
Online ISBN: 978-981-13-7647-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)